Karyopharm (NASDAQ:KPTI) Beats Q1 Revenue, Completes Phase 3 Endometrial Cancer Trial Enrollment

Karyopharm Therapeutics (NASDAQ:KPTI) reported first-quarter 2026 financial results on May 14, beating revenue estimates while simultaneously announcing the completion of enrollment in its Phase 3 XPORT-EC-042 endometrial cancer trial and securing a late-breaking oral presentation slot at the American Society of Clinical Oncology (ASCO) conference. Shares rose 7.3% following the announcement, according to ChartMill.

Q1 2026 Results and Clinical Milestones

• Karyopharm reported a net loss of $22.4 million for the first quarter of 2026, per the company's earnings release filed with the SEC on May 14.
• Q1 2026 revenue came in above analyst estimates, according to ChartMill's reporting on the results.
• The company completed enrollment in its Phase 3 XPORT-EC-042 trial in endometrial cancer, with topline data expected mid-2026, per the company's announcement.
• Phase 3 SENTRY trial results were selected for a late-breaking oral presentation at ASCO in June, according to the company's first-quarter business update.
• The earnings release was accompanied by an investor presentation published on May 14, 2026, covering both financial results and the clinical pipeline update.

What Drove the Results

The completion of enrollment in the XPORT-EC-042 Phase 3 trial marks a significant operational milestone, positioning Karyopharm to deliver topline readout data in the second half of 2026. The selection of SENTRY Phase 3 results for a late-breaking oral presentation at ASCO — one of oncology's most prominent conferences — suggests the data carry meaningful clinical interest, according to the company's announcement.

Together, these two clinical developments arrived alongside a Q1 revenue beat, giving investors concurrent evidence of both commercial execution and pipeline progress. Topline data from XPORT-EC-042 in mid-2026 represents the next major catalyst on the company's near-term calendar, based on the disclosed timeline.

Wall Street View

Analyst sentiment heading into the results was firmly constructive. As of May 1, 2026, the consensus stood at 11 Buy or Strong Buy recommendations against just 2 Hold ratings and no Sell ratings, reflecting broad confidence in Karyopharm's pipeline trajectory. No updated price targets were available following the Q1 report.

Investor Takeaway

Karyopharm enters the second half of 2026 with two high-profile clinical catalysts approaching — mid-year topline data from XPORT-EC-042 and the ASCO presentation of SENTRY Phase 3 results — alongside a Q1 revenue beat that demonstrated the business is executing ahead of estimates. With an 11-to-2 Buy-to-Hold analyst consensus on record and TTM revenue growth of 11.6% (TTM — may not reflect latest quarter), the setup heading into these readouts will likely keep investor attention firmly on clinical outcomes over the coming months.